Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Briquilimab in Chronic Urticaria (Open-Label Extension)
NCT06736262Phase 2Terminated
- Sponsor
- Jasper Therapeutics, Inc.
- Start
- Nov 2024
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of briquilimab in chronic urticaria (CU), sponsored by Jasper Therapeutics, Inc.. Started Nov 2024; status: terminated.
02
Drugs
briquilimab
03
Conditions
chronic urticaria (CU)
Beyond the preview
Go deeper on NCT06736262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06736262.